Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

NCT05904080 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05904080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05904080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Suspended
Start date
February 19, 2024
Completion date
June 16, 2028
Enrollment
50 (estimated)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nasopharyngeal carcinoma, recurrent nasopharyngeal carcinoma, stage iv nasopharyngeal carcinoma ajcc v8